Lomitapide, relief pitcher for patients with homozygous familial hypercholesterolemia

Sang-Hyun Kim,Sang Hong Baek

DOI: https://doi.org/10.1177/2047487319881240

IF: 8.526

2019-10-11

European Journal of Preventive Cardiology

Abstract:Homozygous familial hypercholesterolemia (HoFH) is a rare and life-threatening disease originally characterized clinically by plasma cholesterol levels &gt;13 mmol/L (&gt;500 mg/dL), extensive xanthomas, and marked premature and progressive atherosclerotic cardiovascular disease (ASCVD). Studies in these patients showed a severe defect in the ability to bind and internalize low-density lipoprotein (LDL) particles, caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR).^{<a class="ref showRefEvent2" href="#">1</a>} Recent genetic insights indicate that mutations in alleles of other genes, including APOB, proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDLRAP1, may be present in some individuals with HoFH.^{<a class="ref showRefEvent2" href="#">2</a>,<a class="ref showRefEvent2" href="#">3</a>}

cardiac & cardiovascular systems